Studies

  1. Combined Therapy Paclitaxel Plus Carboplatin for the Treatment of Ovarian Cancer (Phase IV Clinical Study)
  2. Epidemiology of HIV/AIDS in Romania 1985-2006
  3. Use of Intronic Micro RNAs as Cancer Biomarkers

Summary

A phase IV clinical trial was conducted to determine the efficacy of combined treatment paclitaxel plus carboplatin for the treatment of FIGO stages IIC-IV ovarian cancer in 73 women ages 22-73 years old (mean age 53). Paclitaxel and carboplatin were administered by 6 rounds of infusion once every three weeks at the recommended doses of 175 mg/m2 and at AUC=6 (target), respectively. The most common side effects were anemia, neuropathy, and nausea and vomiting. Overall and progression-free survival occurred in 83.3% of all patients that completed the study. The study concludes that the combination chemotherapy used in the SIN-PAC-02 trial is highly effective in the treatment of ovarian cancer.

 

 

Summary

A comprehensive report of HIV/AIDS statistics in Romania was compiled in order to monitor the spread of the disease, improve reporting and help identify at risk populations. The report includes government statistics beginning with the first reported cases of HIV. The efficiency of programs initiated before and after the year 2000 is highlighted and compared to similar programs in European countries that were similarly affected by the HIV/AIDS epidemic.

 

 

Summary

Micro RNAs (miRNAs) are recently described short, 19-22 nucleotide double stranded RNAs that are estimated to control productive synthesis of 10-30% of all cellular proteins. While the analysis of gene expression using microarrays has become routine and will continue to emerge as one of the foremost tools for disease classification and therapeutic outcome prediction, the use of miRNAs is still in its inception. Although gene expression analyses based on miRNAs are anticipated to become a promising complement to mRNA analysis, there are currently obstacles due to poorly-understood miRNA transcriptional regulation events and the lack of a unitary mRNA/miRNA platform. The study explores the use of intronic miRNAs as biomarkers in a variety of malignancies using published microarray studies as well as original findings